close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
EUROPEAN COMMISSION CHIEF URSULA VON DER LEYEN ASSURES AID TO FLOOD-STRICKEN SLOVENIA DURING VISIT
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.
The GlaxoSmithKline logo is seen in this illustration, Aug. 10, 2022. (REUTERS/Dado Ruvic/Illustration/File Photo)
Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
CLICK HERE TO GET THE FOX NEWS APP
Cargo theft is no longer just about stolen trucks and forged paperwork. Over the past…
Amazon has agreed to pay $2.5 billion to settle allegations brought by the Federal Trade…
Sportswear and fitness brand Under Armour is investigating claims of a massive data breach after…
IN TODAY’S NEWSLETTER: - Amazon to cut 16,000 roles as it looks to invest in…
YouTube is rolling out new parental controls designed to give families more say over how…
What happens when artificial intelligence (AI) moves from painting portraits to designing homes? That question…